

Cyclophosphamide



Essential medicine status ✓

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc

ATC codes: L01AA01

Indication	Rhabdomyosarcoma primary site ICD11 code: 2C25.Z
INN	Cyclophosphamide
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection Oral > Solid > dosage form: 25 mg ; 50 mg
EML status history	First added in 1977 (TRS 615) Changed in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2021 (TRS 1035) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents. ↗

Tags

Cancer

Wikipedia

Cyclophosphamide ↗

DrugBank

Cyclophosphamide ↗

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for oral dosage forms of cyclophosphamide on the EML and EMLc be amended to replace 'tablet' with 'solid oral dosage form' to reflect the availability also of capsules and allow greater flexibility in procurement.

Expert Committee report ↗

